The Quantellect read.As of Nov 19, 2026, 6 active firms cover Immunic Inc: 5 rate it Buy or better, 1 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. The target range is very wide, $2.50 to $45.00 (about 18.0x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $17.92 sits 138% above the current $7.52. The rating mix has stayed broadly stable, with Buy-side ratings easing from 6 to 5 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.72 next quarter toward $-2.39 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS6 active firms
Buy
Strong Buy00%
Buy583%
Neutral117%
Sell00%
Strong Sell00%
Based on 6 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$17.92
+138.3% upside
Average target across 6 active firms as of Nov 19, 2026 vs $7.52 current
Highest Target$45.00
Average Target$17.92
Lowest Target$2.50
Detailed analyst forecasts for IMUX
Showing 1–6 of 6 named analysts shown · 6 active firms in the rating projection
As of Nov 19, 2026, 5 of 6 active firms rate IMUX a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
IMUX EPS & revenue forecast
EPS · NEXT QUARTER
$-0.72
Range $-1.20 – $-0.45 · 5 analysts · -33% YoY
Next period, 5 analysts expect Immunic Inc to earn $-0.72 a share (range $-1.20 – $-0.45), versus $-1.08 a year earlier. Full-year consensus is $-3.60, growing to $-2.39 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 5 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering Immunic Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on IMUX.
#1
Yatin Suneja
Guggenheim · Rank #84
Buy
$70.00+830.9% to target
Overall win rate
50%
+ Follow
#2
MC
Matthew Caufield
HC Wainwright & Co. · Rank #155
Buy
$22.00+192.6% to target
Overall win rate
49%
+ Follow
#3
Jason Kolbert
D. Boral Capital · Rank #562
Neutral
No targeton IMUX
Overall win rate
22%
+ Follow
#4
Aydin Huseynov
Ladenburg Thalmann · Rank #564
Buy
$30.00+298.9% to target
Overall win rate
32%
+ Follow
#5
MM
Myles Minter
William Blair
Buy
No targeton IMUX
Coverage
—
+ Follow
IMUX stock forecast FAQ
What is IMUX's average 12-month price target?+
The 6 active firms with a live target average $17.92 for Immunic Inc over the next 12 months, ranging from a $45.00 high to a $2.50 low, as of Nov 19, 2026.
Is IMUX stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 6 active firms as of Nov 19, 2026, 5 rate it Buy or Strong Buy, 1 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for IMUX?+
The Street-high target is $45.00 (Wedbush), and the Street-low is $2.50 (Stifel). The average of all 6 active-firm targets is $17.92.
How many active Wall Street firms cover IMUX?+
6 active firms have a recognized rating on Immunic Inc as of Nov 19, 2026, and 6 active firms carry a live 12-month price target.
Who is the most accurate analyst covering IMUX?+
Among analysts who currently cover IMUX, Yatin Suneja of Guggenheim has the strongest overall Quantellect track record (Rank #84). Their current call is Buy with a $70.00 target.
What is Immunic Inc's projected EPS for next quarter?+
The consensus estimate is $-0.72 per share (range $-1.20 – $-0.45) across 5 analysts. Full-year EPS is projected at $-3.60, rising to $-2.39 the following year.
How much revenue is Immunic Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading IMUX lately?+
As of Nov 19, 2026, 5 of 6 active firms rate IMUX a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their IMUX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.